GLP-1 receptor agonists

The World Health Organization has finally made its recommendations on using GLP-1 therapeutics for weight loss, though it remains to be seen whether it changes their status for prescribing or price. And scientists still have some concerns.

Scientists have failed to show that weight-loss wonder drug semaglutide can also slow the progress of Alzheimer's disease (AD), as two two-year clinical trials end in disappointment for patients, medical scientists and drugmaker Novo Nordisk.

Some people don’t lose enough weight after bariatric surgery, but a new study shows that adding a daily shot of GLP-1 drug liraglutide can help patients shed extra pounds and may reduce the need for further surgery.

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke.

A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without adding side effects – in a mid-stage clinical trial, pointing to a powerful new combination approach to tackling obesity.

It looks like we'll see oral GLP-1 drugs on the market by 2026, with Eli Lilly reporting impressive results from a large, robust 72-week trial that saw obese patients lose an average of 27.3 lb, or 12.4% of their body weight, with a once-daily pill.

Byproducts from gut bacteria breaking down tryptophan, a dietary amino acid, can restore hormone-secreting gut cells reduced by obesity, a new study found. It opens the door to a natural, side-effect-free alternative to GLP-1 drugs like Ozempic.

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial. In the trial, participants lost an average of 3% fat mass in two weeks.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost fitness and can cause serious muscle loss, potentially undermining the long-term health benefits of slimming down.

A current weight-loss and diabetes drug has become a surprise candidate for effective migraine treatment, with a new study showing that the GLP-1 receptor agonist provided significant relief to sufferers of these debilitating, severe headaches.

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating cognitive decline, and it furthers our understanding of why GLP-1 weight loss drugs appear to provide a shield against Alzheimer's disease.

A new drug from pharma company Amgen shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.